Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

NCT05359146 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Neoplasia's (NENs)
Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Interventions

DRUG: 161Tb-DOTA-LM3
DRUG: 177Lu-DOTATOC

Sponsor

University Hospital, Basel, Switzerland

Collaborators

[object Object]
[object Object]